Omnicell (NASDAQ:OMCL) Stock Rating Lowered by Zacks Research

Omnicell (NASDAQ:OMCL) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other analysts also recently commented on OMCL. UBS Group set a $53.00 target price on Omnicell in a research note on Friday, January 16th. Benchmark increased their price objective on Omnicell from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, February 2nd. Bank of America upgraded Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price objective for the company in a report on Wednesday, February 4th. Wall Street Zen downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Wells Fargo & Company lifted their price target on shares of Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Omnicell has a consensus rating of “Moderate Buy” and an average target price of $54.29.

Omnicell Stock Down 0.8%

Shares of NASDAQ OMCL traded down $0.30 during trading on Monday, reaching $38.71. The company had a trading volume of 184,162 shares, compared to its average volume of 685,525. Omnicell has a 12-month low of $22.66 and a 12-month high of $55.00. The company has a quick ratio of 1.22, a current ratio of 1.43 and a debt-to-equity ratio of 0.14. The business’s 50-day moving average is $46.24 and its 200 day moving average is $37.24. The stock has a market cap of $1.74 billion, a PE ratio of 966.12, a P/E/G ratio of 1.21 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). The firm had revenue of $313.98 million during the quarter, compared to the consensus estimate of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 EPS. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. As a group, equities analysts forecast that Omnicell will post 1.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Omnicell news, EVP Corey J. Manley sold 6,106 shares of the company’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $49.90, for a total value of $304,689.40. Following the completion of the sale, the executive vice president owned 91,674 shares in the company, valued at $4,574,532.60. This represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 2.52% of the company’s stock.

Institutional Investors Weigh In On Omnicell

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OMCL. AQR Capital Management LLC boosted its position in shares of Omnicell by 42.1% in the first quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock worth $627,000 after purchasing an additional 5,311 shares during the period. Empowered Funds LLC lifted its stake in shares of Omnicell by 14.3% during the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock valued at $348,000 after buying an additional 1,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Omnicell by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock valued at $4,337,000 after buying an additional 4,866 shares in the last quarter. Jane Street Group LLC increased its stake in Omnicell by 201.5% in the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock worth $5,722,000 after buying an additional 109,382 shares in the last quarter. Finally, Inspire Investing LLC raised its holdings in Omnicell by 33.9% during the second quarter. Inspire Investing LLC now owns 13,224 shares of the company’s stock valued at $389,000 after acquiring an additional 3,346 shares during the period. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.